4d Molecular Therapeutics Inc.
- Address
- 5858 Horton Street
Sponsor Overview
Specializations
Ophthalmic Gene Therapy
The sponsor is actively engaged in developing advanced gene therapy solutions for inherited retinal diseases. Their research portfolio focuses on addressing genetic mutations that lead to progressive vision loss and blindness. The company's therapeutic approach targets specific genetic disorders of the retina through innovative molecular interventions designed to restore or preserve visual function in affected patients.
- Inherited Retinal Degenerations
- X-Linked Retinal Disorders
- Progressive Vision Loss Conditions
The sponsor's work emphasizes the development of targeted therapies for rare ophthalmic genetic conditions that currently have limited treatment options. Their research aims to address the underlying molecular causes of vision impairment through precision medicine approaches, focusing on conditions that affect the photoreceptor cells and retinal structure.
Molecular Therapeutics for Rare Diseases
The organization concentrates on creating therapeutic interventions for rare genetic disorders with significant unmet medical needs. Their research platform is built around developing treatments for conditions caused by specific gene mutations that result in severe functional impairment. The sponsor's work in this domain reflects a commitment to addressing diseases that affect small patient populations but have devastating clinical consequences.
- X-Linked Genetic Conditions
- Rare Hereditary Syndromes
- Genetic Vision Disorders
Their therapeutic development focuses on conditions where conventional treatment approaches have proven inadequate, targeting the fundamental molecular pathways responsible for disease progression. The sponsor's research emphasizes conditions characterized by progressive functional decline and significant impact on quality of life.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase 3 Randomized Trial of Intravitreal 4D-150 vs. Aflibercept in Adults with Neovascular Age-Related Macular Degeneration |  Bulgaria France Germany Hungary Italy Latvia Lithuania Portugal Spain | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 33 sites across their trial portfolio.
Therapeutic Focus
- 1.Eye Diseases1 trial138 other sponsors
Partnered Research Centres
33 centres- Address
- Azinhaga De Santa Comba, 3000-548 Coimbra
- Address
- Via Giovanni Battista Grassi 74, 20157 Milan
- Address
- Georg-Baumgarten-Strasse 3, Flughafen, 60549 Frankfurt
- Address
- Maglodi Ut 89-91, Kerulet, 1106 Budapest
- Address
- Vaci Ut 76, Kerulet, 1133 Budapest
- Address
- 151 Route De Saint Antoine, 06200 Nice
Want to get in touch with this sponsor?
Send a question and we'll pass it on to 4d Molecular Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.